Wird geladen...
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
BACKGROUND: Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)‐antagonist therapy in Crohn's disease (CD). AIM: To compare safety and effectiveness of vedolizumab and TNF‐antagonist therapy in adult CD patients. METHODS: Retrospective observational cohort (May 2...
Gespeichert in:
| Veröffentlicht in: | Aliment Pharmacol Ther |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7496810/ https://ncbi.nlm.nih.gov/pubmed/32656800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15921 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|